Aduro Biotech Inc. (NASDAQ:ADRO) Receives Consensus Recommendation of “Hold” from Analysts
Aduro Biotech Inc. (NASDAQ:ADRO) has received an average recommendation of “Hold” from the eight analysts that are presently covering the firm. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $20.00.
Several equities research analysts have commented on the stock. FBR & Co reaffirmed a “buy” rating and issued a $34.00 target price (up previously from $30.00) on shares of Aduro Biotech in a research note on Saturday, May 14th. Zacks Investment Research downgraded shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Roth Capital reaffirmed a “buy” rating and issued a $22.00 target price (down previously from $46.00) on shares of Aduro Biotech in a research note on Monday, May 16th. Leerink Swann reaffirmed an “outperform” rating and issued a $14.00 target price (down previously from $48.00) on shares of Aduro Biotech in a research note on Tuesday, May 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $30.00 target price on shares of Aduro Biotech in a research note on Friday, August 5th.
Aduro Biotech (NASDAQ:ADRO) traded down 3.01% during midday trading on Friday, hitting $14.50. 78,960 shares of the company traded hands. The stock’s 50-day moving average is $14.82 and its 200-day moving average is $13.24. The firm’s market capitalization is $938.93 million. Aduro Biotech has a 12-month low of $7.26 and a 12-month high of $34.95.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/09/aduro-biotech-inc-nasdaqadro-receives-consensus-recommendation-of-hold-from-analysts.html
Aduro Biotech (NASDAQ:ADRO) last issued its earnings results on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.21. Aduro Biotech had a negative net margin of 23.69% and a negative return on equity of 9.23%. The firm earned $39 million during the quarter, compared to the consensus estimate of $25.24 million. The business’s revenue was up 306.3% compared to the same quarter last year. Analysts anticipate that Aduro Biotech will post ($1.39) EPS for the current fiscal year.
In related news, insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $15.18, for a total value of $379,500.00. Following the completion of the transaction, the insider now owns 12,500 shares of the company’s stock, valued at $189,750. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.50% of the stock is currently owned by corporate insiders.
Aduro Biotech Company Profile
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Ratings for Aduro Biotech Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aduro Biotech Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.